

REMARKS/ARGUMENTS

Claims 13-15, 18-22, 25, 26, 74-78, and 80-82 are currently pending. Claim 75 is allowed. In this Amendment, claims 13, 76-78, and 80-82 are amended.

Rejection Under 35 U.S.C. §112

Claims 13-15, 18-22, 25-26, 74, 76-78, and 80-82 were rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite. This rejection is traversed.

The amended claims indicate that certain features pertain to the monoclonal antibody which competes with MAb 763-15-5. Applicants submit the amended claims are clear of any uncertainty, as indicated by page 4 of the Office Action.

Based on the above, Applicants also submit that the amended claims are novel and nonobvious, as suggested by page 4 of the Office Action.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 303-571-4000.

Respectfully submitted,

/Nathan S. Cassell/

Nathan S. Cassell
Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 415-576-0300

61661856 v1